Lee M. Zehngebot

Hematology Oncology
2501 N Orange Ave
Suite 381
Orlando, FL 32804

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).

Journal: Nature communications
Published: July 28, 2020

Targeting the mTOR pathway in Chromophobe Kidney Cancer.

Targeting the mTOR pathway in Chromophobe Kidney Cancer.

Journal: Journal of Cancer
Published: March 17, 2012
Showing 1-2 of 2

Last Updated: 09/26/2026